The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

As many turn away from tampons and pads – due to toxic chemicals, waste, or price – menstrual cups are emerging as a greener, ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.